Physician profile
Thomas Mccormick
NPI 1295720506
$2,728.15
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $292 · 2021: $794 · 2022: $686 · 2023: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $509.77 | 2021-2023 | Qelbree |
| Corium, LLC | $396.17 | 2021-2023 | Azstarys |
| Tris Pharma INC | $369.37 | 2019-2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $338.53 | 2019-2022 | |
| Neos Therapeutics, LP | $236.96 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $129.85 | 2019-2023 | Jornay Pm |
| Sanofi Pasteur INC. | $118.09 | 2021-2023 | |
| Glaxosmithkline, LLC. | $96.18 | 2019-2023 | Bexsero |
| Adlon Therapeutics L.P. | $80.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $70.66 | 2021-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Kaleo, INC. | $53.06 | 2019-2022 | |
| Sobi, INC | $44.63 | 2019-2023 | |
| Seqirus USA INC | $42.33 | 2021-2023 | Flucelvax Quadrivalent |
| Pfizer INC. | $41.18 | 2019-2023 | |
| Rhodes Pharmaceuticals L.P. | $35.53 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $34.74 | 2019 | |
| Dermira, INC. | $28.77 | 2019-2020 | |
| Phadia US INC. | $25.25 | 2023 | Immunocap |
| Cranial Technologies, INC | $22.03 | 2023 | Doc Band |
| Ultragenyx Pharmaceutical INC. | $16.23 | 2022 | |
| Avion Pharmaceuticals | $13.61 | 2023 | Methylphenidate Hydrochloride |
| Alfasigma USA, INC. | $13.15 | 2021 | |
| Mission Pharmacal Company | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mccormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.